公开(公告)号：US11773082B2

公开(公告)日：2023-10-03

申请号：US17235846

申请日：2021-04-20

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

CPC classification number: C07D403/12 ,  A61P35/00 ,  C07D413/12 ,  C07B2200/07

Abstract: This invention relates to compounds of Formula (I)






and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20160376254A1

公开(公告)日：2016-12-29

申请号：US15262230

申请日：2016-09-12

Applicant: Pfizer Inc.

Inventor： Michael Raymond COLLINS ,  Robert Steven Kania ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Daniel Tyler Richter ,  Scott Channing Sutton ,  Martin James Wythes

IPC: C07D401/06 ,  C07D409/14 ,  C07D413/14 ,  C07B59/00 ,  C07D405/14 ,  C07D401/14

CPC classification number: C07D405/14 ,  C07B59/002 ,  C07B2200/05 ,  C07D401/06 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract translation: 其中R 1，R 2，R 3，R 4，L，X和Z如本文所定义，及其药学上可接受的盐，包含这些化合物和盐的药物组合物，以及使用这些化合物，盐和组合物进行治疗的方法 的细胞生长异常，包括癌症。

公开(公告)号：US09481666B2

公开(公告)日：2016-11-01

申请号：US14740439

申请日：2015-06-16

Applicant: PFIZER INC.

Inventor： Robert Steven Kania ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Scott Channing Sutton ,  Martin James Wythes

IPC: C07D401/06 ,  C07D401/14 ,  A61K31/44 ,  A61K31/47 ,  C07D405/14 ,  C07D413/14 ,  C07D409/14

CPC classification number: C07D405/14 ,  C07B59/002 ,  C07B2200/05 ,  C07D401/06 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract translation: 本发明涉及其中R1，R2，R3，R4，L，X和Z如本文所定义的通式（I）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物，以及方法 使用这些化合物，盐和组合物来治疗异常细胞生长，包括癌症。

公开(公告)号：US11492346B2

公开(公告)日：2022-11-08

申请号：US16902515

申请日：2020-06-16

Applicant: Pfizer Inc. ,  CTXT PTY LTD

Inventor： Ylva Elisabet Bergman Bozikis ,  Michelle Ang Camerino ,  Pei-Pei Kung ,  Paul Anthony Stupple ,  Scott Channing Sutton

IPC: C07D413/06 ,  A61P35/04 ,  A61K45/06

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ring A, R1-R8, and n are defined herein. The novel benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.

公开(公告)号：US11014911B2

公开(公告)日：2021-05-25

申请号：US16774786

申请日：2020-01-28

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US10570121B2

公开(公告)日：2020-02-25

申请号：US16156304

申请日：2018-10-10

Applicant: Pfizer Inc.

Inventor： Michael Raymond Collins ,  Robert Steven Kania ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Daniel Tyler Richter ,  Scott Channing Sutton ,  Martin James Wythes

IPC: C07D401/06 ,  C07B59/00 ,  A61K31/4725 ,  C07D405/14 ,  C07D401/14 ,  C07D413/14 ,  C07D409/14

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20150361067A1

公开(公告)日：2015-12-17

申请号：US14740439

申请日：2015-06-16

Applicant: PFIZER INC.

Inventor： Michael Raymond Collins ,  Robert Steven Kania ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Daniel Tyler Richter ,  Scott Channing Sutton ,  Martin James Wythes

IPC: C07D401/06 ,  C07D409/14 ,  C07D413/14 ,  C07D405/14 ,  C07D401/14

CPC classification number: C07D405/14 ,  C07B59/002 ,  C07B2200/05 ,  C07D401/06 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

Abstract translation: 本发明涉及其中R1，R2，R3，R4，L，X和Z如本文所定义的通式（I）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物，以及方法 使用这些化合物，盐和组合物来治疗异常细胞生长，包括癌症。

公开(公告)号：US20150239842A1

公开(公告)日：2015-08-27

申请号：US14430799

申请日：2013-09-16

Applicant: PFIZER INC.

Inventor： Martin Paul Edwards ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Indrawan James Mcalpine ,  Eugene Yuanjin Rui ,  Scott Channing Sutton ,  John Howard Tatlock ,  Martin James Wythes

IPC: C07D213/64 ,  C07D487/08 ,  C07D491/08 ,  C07D405/14 ,  C07D413/14 ,  C07D401/12 ,  C07D401/14

CPC classification number: C07D401/14 ,  C07D213/64 ,  C07D401/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/14 ,  C07D413/14 ,  C07D487/08 ,  C07D491/08

Abstract: This invention relates to compounds of general formula (I), in which R1, R2, R6, U, V, W, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds and salts, and to methods of using such compounds, salts and compositions.

Abstract translation: 本发明涉及通式（I）的化合物，其中R1，R2，R6，U，V，W，X，Y和Z如本文所定义，及其药学上可接受的盐，含有这些化合物和盐的药物组合物 以及使用这些化合物，盐和组合物的方法。